Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCD601 (siplizumab) vs rATG as induction in de novo renal transplant recipients
2020-000419-56Phase 2Active
- Sponsor
- ITB-MED
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siplizumab (2 arms), sponsored by ITB-MED. Primary endpoint: Adverse events. Started Dec 2020; status: active.
02
Drugs
siplizumab
Beyond the preview
Go deeper on 2020-000419-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000419-56.